Does REPAGLINIDE Cause Malignant neoplasm progression? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Malignant neoplasm progression have been filed in association with REPAGLINIDE (Repaglinide). This represents 0.4% of all adverse event reports for REPAGLINIDE.
9
Reports of Malignant neoplasm progression with REPAGLINIDE
0.4%
of all REPAGLINIDE reports
1
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From REPAGLINIDE?
Of the 9 reports, 1 (11.1%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REPAGLINIDE. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does REPAGLINIDE Cause?
Hypoglycaemia (665)
Acute kidney injury (281)
Lactic acidosis (163)
Hypoglycaemic coma (125)
Sopor (91)
Confusional state (89)
Drug interaction (89)
Blood glucose increased (88)
Diarrhoea (87)
Dyspnoea (87)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which REPAGLINIDE Alternatives Have Lower Malignant neoplasm progression Risk?
REPAGLINIDE vs REPOTRECTINIB
REPAGLINIDE vs REQUIP
REPAGLINIDE vs RESLIZUMAB
REPAGLINIDE vs RESMETIROM
REPAGLINIDE vs RESTASIS